{
    "root": "2f265ea8-172b-172f-e063-6394a90ad988",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levetiracetam",
    "value": "20250227",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555"
        }
    ],
    "indications": "levetiracetam tablets indicated treatment partial-onset seizures patients 1 month age older ( 1.1 ) levetiracetam tablets indicated adjunctive therapy treatment : \u2022 myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) \u2022 primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
    "contraindications": "\u2022 oral solution pediatric patients body weight \u2264 20 kg ( 2.1 ) \u2022 pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) partial-onset seizures ( monotherapy adjunctive therapy ) \u2022 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) \u2022 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) \u2022 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) \u2022 adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older \u2022 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures \u2022 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) \u2022 adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.4 ) adult patients impaired renal function \u2022 dose adjustment recommended , based patient \u2019 estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions": "levetiracetam tablets usp , 1000 mg white colored , oblong shaped , scored , film coated tablets debossed ' h ' one side '91 ' side . supplied containers ndc : 70518-1901-00 ndc : 70518-1901-01 ndc : 70518-1901-02 packaging : 30 1 blister pack packaging : 30 1 box packaging : 1 1 pouch store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "levetiracetam tablets contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Levetiracetam tablets are indicated for adjunctive therapy for the treatment of: \u2022\u00a0Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) \u2022\u00a0Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 )",
    "contraindications_original": "\u2022\u00a0Use the oral solution for pediatric patients with body weight \u2264 20 kg ( 2.1 ) \u2022\u00a0For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) ( 2.1 ) Partial-Onset Seizures (monotherapy or adjunctive therapy) \u2022\u00a01 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily ( 2.2 ) \u2022\u00a06 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily ( 2.2 ) \u2022\u00a04 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.2 ) \u2022\u00a0Adults 16 Years and Older: 500 mg twice daily; increase by\u00a0 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily ( 2.2 ) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older \u2022\u00a0500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.3 ) Primary Generalized Tonic-Clonic Seizures \u2022\u00a06 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.4 ) \u2022\u00a0Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.4 ) Adult Patients with Impaired Renal Function \u2022\u00a0Dose adjustment is recommended, based on the patient\u2019s estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions_original": "Levetiracetam tablets USP, 1000 mg are white colored, oblong shaped, scored, film coated tablets debossed with\u00a0 'H'\u00a0 on one side and '91' on other side. They are supplied in containers of\n                  NDC: 70518-1901-00\n                  NDC: 70518-1901-01\n                  NDC: 70518-1901-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema\n \n  [see Warnings and Precautions (\n  \n   5.4)]\n \n  ."
}